Main Article Content
Socioeconomic status (SES) is reflecting differences in sociodemographic factors affecting cancer survivorship. Deprived, low SES populations has a higher prevalence of multiple myeloma and worst survival, a gap that widens over time.
Methods: We performed a meta-analysis of 16 studies (registries and cohorts) reporting survival data of myeloma patients according to SES. Ten studies reported Hazzard Ratio (HR) (95 % CI) and 16 studies reported p values. We combined the HR from 10 studies and by using the Mosteller-Bush formula we performed the synthesis of p values according to the area of the globe.
Results: A combination of HR from 10 studies including 85198 myeloma patients weighted to sample size of each study and adopting the hypothesis of random effect returned a combined HR: 1,26 (1,13-1,31) in favor of high SES patients.
USA: Synthesis of p values coming from 6 studies (n=89807 pts) by using the Mosteller and Bush formula extracted a p-value of <0.0001 favoring high SES patients
Oceania: Synthesis of p values in two cohorts from Australia and New Zealand (n= 10196 pts) returned a p-value of 0,022 favoring high SES patients
Europe: The synthesis of p values from UK and Greece studies (n=18533 pts) returned a p-value of <0,0001 favoring high SES patients
Asia: Synthesis of 2 studies from Asia (n=915 pts) returned a p-value of <0,0001 favoring high SES patients
Conclusions: Across the globe and widening over decades socioeconomic status remains a gap for equality in myeloma care
Downloads month by month
2. Moreau P, San Miguel J, Sonneveld P et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv52-iv61.
3. Ailawadhi S, Azzouqa AG, Hodge D et al. Survival Trends in Young Patients With Multiple Myeloma: A Focus on Racial-Ethnic Minorities. Clin Lymphoma Myeloma Leuk 2019; 19: 619-623.
4. Sun T, Wang S, Sun H et al. Improved survival in multiple myeloma, with a diminishing racial gap and a widening socioeconomic status gap over three decades. Leuk Lymphoma 2018; 59: 49-58.
5. Costa LJ, Brill IK, Brown EE. Impact of marital status, insurance status, income, and race/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States. Cancer 2016; 122: 3183-3190.
6. Hong S, Rybicki L, Abounader D et al. Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant 2016; 22: 1141-1144.
7. Savage D, Lindenbaum J, Van Ryzin J et al. Race, poverty, and survival in multiple myeloma. Cancer 1984; 54: 3085-3094.
8. Nandakumar A, Armstrong BK, de Klerk NH. Multiple myeloma in Western Australia: a case-control study in relation to occupation, father's occupation, socioeconomic status and country of birth. Int J Cancer 1986; 37: 223-226.
9. Harwood M, Dunn N, Moore J et al. Trends in myeloma relative survival in Queensland by treatment era, age, place of residence, and socioeconomic status. Leuk Lymphoma 2019; 1-7.
10. Renshaw C, Ketley N, Moller H, Davies EA. Trends in the incidence and survival of multiple myeloma in South East England 1985-2004. BMC Cancer 2010; 10: 74.
11. Rachet B, Mitry E, Shah A et al. Survival from multiple myeloma in England and Wales up to 2001. Br J Cancer 2008; 99 Suppl 1: S110-112.
12. Chan HSH, Milne RJ. Impact of age, sex, ethnicity, socio-economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand. Br J Haematol 2019.
13. Nair MK, Varghese C, Krishnan E et al. Survival in multiple myeloma in Kerala. Natl Med J India 1993; 6: 7-10.
14. Abou-Jawde RM, Baz R, Walker E et al. The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. Haematologica 2006; 91: 1410-1413.
15. Intzes S, Symeonidou M, Zagoridis K et al. Socioeconomic Status Is an Independent Prognostic Factor for Overall Survival in Patients With Multiple Myeloma: Real-World Data From a Cohort of 223 Patients. Clin Lymphoma Myeloma Leuk 2020.